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The molecular basis of cytochrome c oxidase (COX,
complex IV) deficiency remains genetically undeter-
mined in many cases. Homozygosity mapping and
whole-exome sequencing were performed in a
consanguineous pedigree with isolated COX defi-
ciency linked to a Leigh syndrome neurological
phenotype. Unexpectedly, affected individuals
harbored homozygous splice donor site mutations
in NDUFA4, a gene previously assigned to encode
a mitochondrial respiratory chain complex I (NADH:
ubiquinone oxidoreductase) subunit. Western blot
analysis of denaturing gels and immunocytochem-
istry revealed undetectable steady-state NDUFA4
protein levels, indicating that the mutation causes
a loss-of-function effect in the homozygous state.
Analysis of one- and two-dimensional blue-native
polyacrylamide gels confirmed an interaction be-
tween NDUFA4 and the COX enzyme complex in
control muscle, whereas the COX enzyme complex
without NDUFA4 was detectable with no abnormal
subassemblies in patient muscle. These observa-
tions support recent work in cell lines suggesting
that NDUFA4 is an additional COX subunit and
demonstrate that NDUFA4 mutations cause human
disease. Our findings support reassignment of the
NDUFA4 protein to complex IV and suggest that pa-
tients with unexplained COX deficiency should be
screened for NDUFA4 mutations.CINTRODUCTION
Cytochrome c oxidase (COX, complex IV) is the terminal enzyme
complex of the mitochondrial respiratory chain and plays a vital
role in cellular energy transformation. Mammalian COX is re-
ported to have a crystal structure comprising 13 polypeptide
subunits (Tsukihara et al., 1996). The three largest subunits are
encoded by the mitochondrial DNA (mtDNA) and form the cata-
lytic core of the enzyme. The remaining ten subunits are nuclear-
encoded and are thought to have a function in assembly/stability
and dimerization of the enzyme, and regulation of the enzyme’s
catalytic activity (Taanman, 1997a). Mutations in the structural
subunits are extremely rare (Hanna et al., 1998; Rahman et al.,
1999) with only three nuclear-encoded COX subunits linked to
human disease (Massa et al., 2008; Shteyer et al., 2009; Indrieri
et al., 2012). To date, most cases of isolated COX deficiency are
caused by mutations in nuclear-encoded proteins required for
COX translation, maturation, or assembly (Soto et al., 2012).
Furthermore, these reported nuclear gene mutations are typi-
cally associated with severe neonatal or childhood-onset pre-
sentations and an early fatal outcome. However, many cases
of COX deficiency remain undefined at the molecular level.
We investigated the genetic basis of neurological disease in a
large consanguineous Pakistani family in whom four affected
relatives had isolated COX deficiency. The natural history was
of an initial presentation with congenital lactic acidosis and
subsequent evolution into a Leigh syndrome (Mendelian
Inheritance in Man [MIM] 256000) neurological phenotype with
bulbar dysfunction, dystonia, ataxia, spasticity, and intermittent
encephalopathy. Whole-mtDNA sequencing was normal, and
genetic analysis of nuclear genes known to cause isolated
COX deficiency did not reveal any pathogenic mutations.ell Reports 3, 1795–1805, June 27, 2013 ª2013 The Authors 1795
RESULTS
Genetic Investigations
Homozygosity Mapping and Whole-Exome Sequencing
Bioinformatic Analysis
To identify areas of shared homozygosity among affected rela-
tives, we genotyped six family members (three affected and
three unaffected, Figure 1A). Two large regions of shared homo-
zygosity mapped to chromosome 7p (nucleotides 9,219,283–
13,801,764, containing 15 protein-coding genes; and nucleo-
tides 19,034,191–29,250,335, containing 92 protein-coding
genes, Table S1). As no candidate genes for COX deficiency
werepresent in either region, itwas initially concluded that a small
area of homozygosity had been overlooked. We therefore under-
took whole-exome sequencing in two affected family members
(III-4 and III-6). Our filtering pathway (Table 1) searched for novel
(not reported to dbSNP132 and/or 1000Genomes, the remaining
UK10K rare disease cohort [823 exomes at the time of the anal-
ysis], or the NHLBI Exome Sequencing Project [ESP] database),
homozygous (in view of parental consanguinity), functional
(nonsynonymous coding and/or loss-of-function), single-nucleo-
tide variants (SNVs) and/or coding insertions/deletions (indels)
shared by both affected siblings.We initially searched genes pre-
dicted to play a role in COX biogenesis. However, using this
strategy no candidate genes were identified across the entire
exome. We subsequently relaxed our filtering strategy to include
all known nuclear-encodedmitochondrial genes (Pagliarini et al.,
2008) and identified a homozygous splice donor site mutation
(c.42+1G/ C, NM_002489.3) in NDUFA4, a gene within one of
our previously identified regions of homozygosity (see Tables
S2 andS3 for coverage of the linkage loci in III-4 and III-6). Sanger
sequencing demonstrated that all four affected individuals were
homozygous for the mutation, whereas three unaffected family
members (II-2, III-1, and III-2) were heterozygous (Figure 2A). A
further 20 probands with isolated COX deficiency were screened
for mutations in NDUFA4, but no further variants were identified.
Transcriptional Analysis of c.42+1G/ C Mutation
To study the effect the c.42+1G / C mutation had on mRNA
splicing, we amplified NDUFA4 complementary DNA (cDNA)
fragments, generated from reverse transcription of mRNA ex-
tracted from whole blood and cultured skin fibroblasts, and
resolved the PCR products on a denaturing 7% polyacrylamide
gel followed by silver staining. This revealed two fragments in
blood: (1) a band measuring 241 bp, corresponding to the
wild-type transcript, which was present in all samples but at
much lower levels in the affected subjects (III-3 and III-4)
compared with an unaffected carrier (II-2) and the control; and
(2) a band at 245 bp that was absent in the control sample but
present at high levels in the affected subjects with lower levels
detectable in the unaffected carrier. Cultured skin fibroblasts
demonstrated a 245 bp fragment in the patient studied (III-4),
with no evidence of wild-type transcript (Figure 2B). Low-level
wild-type cDNA sequence was observed in the sequencing elec-
tropherograms of both affected individuals (Figure 2C, data for
III-3 not shown). These data indicate that the c.42+1G / C
mutation does not appear to completely abolish correct splicing
of NDUFA4 exon 1 to exon 2 in blood. Sanger sequencing of the
PCR products revealed that the first 4 bp of intron 1 are retained1796 Cell Reports 3, 1795–1805, June 27, 2013 ª2013 The Authorsfollowing activation of a cryptic splice site 4 bp downstream of
the c.42+1G/ C mutation (Figures 2A and 2C). This frameshift
is predicted to introduce a premature stop codon (TAA) 105 bp
downstream in exon 3. If translated, the resultant protein would
consist of 14 in-frame amino acids followed by 35 out-of-frame
amino acids (compared to the 81 amino acid wild-type protein).
Western Blot of Denaturing Polyacrylamide Gels and
Immunocytochemistry
NDUFA4 protein was undetectable in all affected subjects exam-
ined (muscle tissue of III-4, III-6, and III-13, cultured skin fibro-
blasts of III-4). Steady-state level of the mitochondrially encoded
COX subunit MTCO2wasmarkedly reduced in themuscle tissue
of onepatient comparedwith themeanMTCO2 value of four con-
trols (MTCO2 level in III-6 56% of controls). The steady-state
MTCO2 subunit levels in III-6 and III-13 were comparable to the
control muscle tissue samples (Figure 3A). Immunocytochem-
istry also showed absent NDUFA4 protein in cultured skin fibro-
blasts (III-4) with normal mitochondrially encoded COX subunit
MTCO1 (Figure 3B). MitoTracker staining confirmed colocaliza-
tion of NDUFA4 in control fibroblasts (data not shown).
In-Gel Activity and Western Blot Analysis of One- and
Two-Dimensional Blue-Native Polyacrylamide Gels
In-gel activity staining of blue-native gels supported spectropho-
tometric analysis of respiratory chain enzymes with normal com-
plex I (NADH:ubiquinone oxidoreductase) and reduced complex
IV in the muscle tissue of affected subjects (III-4 and III-6, Fig-
ure 4A). Recent work suggests an interaction of NDUFA4 with
complex IV that is disrupted when high concentrations (>1.5%)
of n-dodecyl b-D-maltoside (DDM), the standard detergent used
to purify complex IV for crystallization purposes, are used (Balsa
et al., 2012). To establish the optimal concentration of DDM
required to analyze NDUFA4 as part of the COX holoenzyme,
weperformedwesternblot analysis of blue-nativepolyacrylamide
gels loaded with 10 mg of mitochondrial enriched protein pellets
extracted from control muscle tissue using serial dilutions of
DDM for mitochondrial membrane protein extraction (Scha¨gger,
1995;Williams et al., 2004). Blots were developedwith antibodies
directed against NDUFA4 and MTCO1. This analysis demon-
strated that, in our hands, dissociation of NDUFA4 subunit from
complex IV occurred when >0.08% DDM was used to extract
mitochondrial membrane proteins, whereas %0.08% DDM
allowed detection of NDUFA4 as part of complex IV (Figure 4B).
Wesubsequentlyproceededwithwesternblotanalysisof respira-
tory chain enzymes extracted using 0.08%DDM in order to verify
interaction of the NDUFA4 protein with complex IV (Figure 4C).
Analysis of one-dimensional blots of blue-native gels showed
complex IV holoenzyme was present in the muscle tissue of III-4
with no abnormal subassemblies, whereas one- and two-dimen-
sional blots confirmed association of NDUFA4 with complex IV in
the control. NDUFA9, a known structural accessory subunit of
complex I, migrated separately to NDUFA4 on the two-dimen-
sional blots and appeared as a double spot in the patient sample
(Figure 4C). Further experiments with human cell cultures (data
not shown) indicated that the faster migrating spot represents a
proteolytic truncation of NDUFA9, possibly resulting from pro-
longed storage of the patient’s muscle sample.
Figure 1. Pedigree of Family Harboring the c.42+1G/ C Mutation in NDUFA4 and Brain MRI Characteristic of Leigh Syndrome
(A) Patient-reported pedigree of consanguineous family harboring the c.42+1G/ C mutation in NDUFA4 is shown. Arrow indicates proband. Members of the
family whose genotype data were used in homozygosity mapping analyses are illustrated by chromosome 7 schematic. Those whose exomes were sequenced
are marked with an asterisk (*). Filled symbols indicate affected individuals. Square symbols indicate male gender. Round symbols indicate female gender.
Symbols with diagonal strikethrough indicate deceased. Broken line indicates the possibility that III-13 is a more distant cousin.
(B) MR T2-weighted coronal image of brain (III-3), characteristic of Leigh syndrome, demonstrating multiple scattered T2 hyperintensities in deep white matter of
both cerebral hemispheres (arrow, 1), medial thalami (arrow, 2), and at the level of the superior cerebellar peduncles (arrow, 3). Hyperintensities were also evident
in the corticospinal tracts of the pons, right middle cerebellar peduncles, cerebellar hemispheres, and descending tracts at the level of the medulla oblongata
(data not shown). Similar appearances were evident on the brain MRI of the other affected patients.
See also Table S1.
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Table 1. Identification of Shared Candidate Genes for
Cytochrome c Oxidase Deficiency in Subjects III-4 and III-6 with
Exome Resequencing
Filter III-4 III-6
Shared
Variants
Total number of SNVs and indels 140,456 140,859 78,004
Homozygous SNVs and indels 50,868 50,832 28,320
Number of homozygous PASS SNVs
and indels
26,379 25,289 19,389
Novel homozygous PASS SNVs and
indels
442 412 190
Functional novel homozygous PASS
SNVs and indels
46 40 13
Functional novel homozygous PASS
SNVs and indels with predicted
mitochondrial localization
2 2 1
IARS FTSJ2
NDUFA4 NDUFA4 NDUFA4
Indels, insertions/deletions; SNVs, single nucleotide variants. Novel, not
reported to dbSNP132 and/or 1000 Genomes, the remaining UK10K
rare disease cohort (823 exomes at the time of the analysis), or the NHLBI
Exome Sequencing Project database. Functional, nonsynonymous
coding and/or loss-of-function variants.
See also Tables S2 and S3.DISCUSSION
We studied a family with COX-deficient Leigh syndrome not
explained by any previously described gene mutation. Through
a combined homozygosity mapping and whole-exome
sequencing approach, we identified a homozygous splice donor
site mutation in NDUFA4, a gene previously considered to
encode a subunit of respiratory chain complex I. Transcriptional
studies demonstrated the c.42+1G / C transversion signifi-
cantly reduces wild-typeNDUFA4mRNA and produces an aber-
rant transcript that predicts a translated protein comprising 14
in-frame amino acids followed by 35 out-of-frame amino acids.
Western blot analysis of denaturing gels and immunocytochem-
istry revealed undetectable steady-state NDUFA4 protein levels,
indicating that this mutation causes a loss-of-function effect in
the homozygous state.
The existence of some very-low-level wild-type NDUFA4 tran-
scripts in patients harboring the c.42+1G/ C mutation might
explain the slower natural history and the comparatively milder
clinical phenotype observed; most previously reported patients
with nuclear-encoded COX deficiency exhibit severe pheno-
types resulting in early childhood death. Interestingly, mutant
transcript alone was detected in cultured skin fibroblasts,
despite apparently normal fibroblast COX activity observed in
III-4 using a glucose-containing culture medium. Cells cultured
with galactose as a carbon source are not able to produce ATP
through glycolysis and are entirely dependent on oxidative phos-
phorylation (OXPHOS) for their ATP synthesis (Petrova-Benedict
et al., 1992).We therefore repeated the assayswith cells grown in
galactose-containing medium for 6 days in order to accentuate
the underlying defect in OXPHOS. In contrast to III-4 fibroblasts
grown in glucose-containing medium, III-4 fibroblasts grown in1798 Cell Reports 3, 1795–1805, June 27, 2013 ª2013 The Authorsgalactose-containing medium showed a clear COX deficiency.
These observations indicate that current diagnostic procedures
that typically use glucose as a carbon source in the culture me-
dium may not detect a reduction in COX activity.
Balsa and colleagues (2012) found that >1.5% of DDM disrup-
ted the binding of NDUFA4 with complex IV in HeLa cell mito-
chondria, whereas in our hands >0.08% of DDM disrupted the
binding in humanmusclemitochondrial preparations (Figure 4B).
In titration experiments with HeLa cells, we found that >0.04% of
DDM disrupted the binding (data not shown). The discrepancy in
the concentration of DDM required to dissociate NDUFA4
from the COX enzyme complex may be explained by differences
in the buffer conditions used. We carried out our DDM extrac-
tions in 1 M ε-amino-n-caproic acid, 50 mM bistris (pH 7.0)
(Scha¨gger, 1995). The buffer conditions used by Balsa and
colleagues were not specified.
Our data confirm that NDUFA4 is not required for assembly of
the other COX subunits because we detected the fully assem-
bled COX enzyme complex with no abnormal subassemblies
on native gels of patient mitochondrial membrane proteins. In
addition, the observation that COX activity is retained following
its purification (Sinjorgo et al., 1987) using concentrations of
DDM now known to disrupt NDUFA4 implies that NDUFA4 is
not directly required for catalysis per se. However, deficiency
of NDUFA4 clearly impairs COX activity in the muscle tissue
and cultured skin fibroblasts in our patients harboring homozy-
gous loss-of-function NDUFA4mutations. We suggest NDUFA4
is a subunit of COX rather than an assembly factor because blots
of two-dimensional blue-native polyacrylamide gels demon-
strated a clear association between NDUFA4 and the COX
enzyme complex. We also propose that NDUFA4 is required dur-
ing the biogenesis of COX to become an active enzyme and re-
mains loosely associated with the enzyme complex. Apparently,
a critical interaction occurs between NDUFA4 and the remaining
COX subunits during biogenesis of the enzyme complex that is
essential for COX activity. For example, it is possible that
NDUFA4 facilitates folding of MTCO1 or is involved in addition
or modification of prosthetic groups that affects downstream
catalysis but not assembly of the enzyme. The precise nature
of this interaction requires further study.
The discovery that NDUFA4 mutations cause human COX
deficiency indicates an important role of the NDUFA4 protein in
COX function. Our findings are supported by recent mouse
and human cell line evidence that the NDUFA4 protein is actually
an additional COX subunit (Balsa et al., 2012), despite its previ-
ously accepted role as an accessory subunit of complex I (Carroll
et al., 2002). This has important implications for understanding
the precise biological function of the NDUFA4 protein and its
interaction with the other COX polypeptide subunits and assem-
bly factors.We suggest that analysis of theNDUFA4 gene should
be considered in all patients with unexplained COX deficiency.EXPERIMENTAL PROCEDURES
Subjects
The proband (III-4, Figure 1A; Tables 2 and 3) was the fourth child of healthy
first-cousin Pakistani parents. He presented with lactic acidosis at birth
following a normal pregnancy and full-term delivery. Birth weight was 2.7 kg.
There was initial normal motor development, but gait was later considered
‘‘stiff,’’ and at 24 months he was diagnosed with a spastic diplegia. Speech
was delayed and there were moderate learning difficulties. Aged 13 years,
he suffered his first generalized tonic-clonic seizure and subsequently devel-
oped treatment-resistant myoclonus. An electroencephalogram indicated a
right temporal focus with interictal discharges over the right anterior temporal
and frontocentral regions. At 17 years, plasma lactate was 2.4 mmol/l (refer-
ence <2.0), and cerebrospinal fluid (CSF) lactate was 3.2 mmol/l (reference
<2.0). CSF protein was also elevated at 0.54 g/l (reference 0.1–0.3), as was
CSF alanine at 45 mg/l (reference 16–36). Brain CT (13 years) andMRI (17 years)
were both normal. However, a brain MRI at age 25 years demonstrated T2 hy-
perintensities in the deep white matter. Nerve conduction studies indicated
there was a sensory axonal peripheral neuropathy. Muscle biopsy at age 17
years showed nonspecific changes, including increased fiber size variation
and intense peripheral staining of some fibers on modified Gomori trichrome,
although no true ragged red fibers. COX histochemistry was normal. Electron
microscopy revealed lipid droplets in some fibers. Spectrophotometric assay
of muscle confirmed significant COX deficiency (COX/citrate synthase [CS]
ratio 0.008; controls 0.014–0.034), whereas enzyme assays of mitochondrial
respiratory chain complex I and complex II+III (succinate: cytochrome c reduc-
tase), corrected for CS, were normal. Although fibroblast COX activity was
initially found to be normal (COX/CS ratio 2.2; controls >1), a repeat assay us-
ing whole-cell lysate of cultured skin fibroblasts grown on galactose rather
than glucose medium did demonstrate reduced COX activity (1.07 k/min/
mg; control mean ± SD [n = 5]: 3.60 ± 0.24 k/min/mg). Complex I activity in
fibroblasts grown under the same conditions was normal (37.3 nmol/min/
mg; control mean ± SD [n = 5]: 19.4 ± 7.2 nmol/min/mg). Pyruvate dehydroge-
nase activity was retained in cultured skin fibroblasts, andmutations in SURF1
(encoding the surfeit locus protein 1, MIM 185620), POLG (encoding the cata-
lytic subunit of mitochondrial DNA polymerase gamma, MIM 174763),C10orf2
(encoding the DNA helicase Twinkle, MIM 606075), and the entire mitochon-
drial genome were excluded. Most recent clinical examination at age 32 years
showed short stature (5 ft 4 in) and a spastic gait. Cranial nerves were normal.
Upper and lower limb examination revealed dystonic posturing and increased
tone with pyramidal weakness (Medical Research Council [MRC] grade 4/5).
Tendon reflexes were pathologically brisk in arms and legs and plantar re-
sponses extensor.
Three additional affected family members (III-3, III-6, and III-13, Figure 1A;
Tables 2 and 3; Document S1) presented similarly at birth with congenital lactic
acidosis. Two had delayed motor and language skills and developed a com-
bination of dystonia, ataxia, and pyramidal tract signs in later life. All had
mild-moderate learning difficulties. The brain MRI of all three patients was
characteristic of Leigh syndrome with T2 hyperintensities present to variable
degrees in the deep white matter, basal ganglia, thalami, and brainstem (Fig-
ure 1B, III-3 shown). Reduced COX staining in all muscle fibers was seen in III-
13, and isolated COX deficiency was confirmed by spectrophotometric assay
of the muscle tissue from III-6 (0.004 COX/CS; controls 0.014–0.034), with
normal complex I and II+III activity corrected for CS. One individual (III-6)
died of respiratory failure at age 26 years due to presumed extension of exist-
ing and/or new brainstem lesions, whereas a second (III-13) died at age 8 years
9 months following progressive neurological regression with a gradual loss of
motor, language, and cognitive skills.
Standard protocol approvals, registration, and patient consents were
obtained. The study was approved and performed under the ethical guidelines
issued by our institutions. In addition to the index family, a further 20 COX-defi-
cient probands were screened for mutations in NDUFA4.
Histopathology
Muscle biopsies were performed following informed consent, snap-frozen at
the bedside, and stored at 80C until use. Standard histological and histo-
chemical stains were used on cryostat sections as previously described (Rah-
man et al., 2000).
Cell Culture
Skin biopsies were performed following informed consent. Human fibroblasts
were established from skin explants and cultured routinely in Dulbecco’s
modified Eagle’smedium, 4.5 g/l D-(+)-glucose, Glutamax-I (Life Technologies)Csupplemented with 10% fetal bovine serum, 110 mg/ml of sodium pyruvate,
50 U/ml of penicillin, 50 mg/ml of streptomycin, and 50 mg/ml of uridine. For
biochemical assays and immunocytochemistry, the glucose in the medium
was replaced with 4.5g/l of D-(+)-galactose for 6 days. Medium was changed
every 4 days. Cells were grown routinely in plastic dishes at 37C in a humid-
ified atmosphere of 5%CO2 in air but cultured onto glass coverslips for 3 days
prior to immunocytochemical investigations (Taanman et al., 2003). Cultures
were checked for mycoplasma infection by staining prior to all experiments.
Preparation of Crude Mitochondrial Fractions
Frozen muscle tissue was ground in homogenization buffer (320 mM sucrose,
1 mM EDTA, 10 mM Tris-HCl [pH 7.4]) in a glass homogenizer manually. Mus-
cle homogenates were centrifuged at 6003 g for 10 min at 4C. The superna-
tants were stored on ice and the pellets were resuspended in homogenizing
buffer, homogenized, and centrifuged at 600 3 g for 10 min at 4C. Both the
supernatants were mixed and centrifuged at 12,000 3 g for 10 min at 4C.
Crude mitochondrial fractions were isolated from 103 106 cells of the fibro-
blast cultures by differential centrifugation (Rickwood et al., 1987). The mito-
chondrial enriched protein pellets were subsequently used for all biochemical
assays (apart from spectrophotometric enzyme assay of cultured skin
fibroblasts grown on galactose medium where whole-cell lysates were
used), in-gel activity staining, and western blot analysis of SDS-denaturing
and blue-native polyacrylamide gels. Protein concentrations were determined
by Bradford assay.
Biochemical Assays
Spectrophotometric enzyme assays of mitochondrial respiratory chain com-
plex I, complex II+III, and complex IV activities corrected for CS were per-
formed as previously described (Hargreaves et al., 2002). In-gel activity of
complex I and IV was measured as previously described (Zerbetto et al.,
1997). The staining intensity of each band was quantified using AlphaEase
FC software from Alpha Innotech.
Genetics Investigations
Homozygosity Mapping
Total genomic DNA (gDNA) was extracted from peripheral blood leucocytes
using standard extraction protocols. We genotyped subjects II-2, III-1, III-2,
III-3, III-4, and III-6 using the Illumina 740K OmniExpress single nucleotide
polymorphism (SNP) array according to the manufacturer’s instructions and
our previous publications (Paisan-Ruiz et al., 2009). All files were visually
examined in GenomeViewer tool within BeadStudio v3.1 Genotyping module
(Illumina), where twometrics were assessed: logR ratio and B allele frequency.
The log R ratio gives an indirect measure of copy number of each SNP by plot-
ting the ratio of observed to expected hybridization intensity. B allele frequency
plots the proportion of times an allele is called B at each SNP locus: thus, the
expected values are 1.0 (B/B), 0.5 (A/B), and 0.0 (A/A). These two statistics
allow visualization of copy number changes and homozygosity mapping. After
quality control, our first analysis was visual inspection to determine whether
any large insertions/deletions were present, and whether any extended re-
gions of homozygosity were shared by affected individuals and absent in
unaffected family members. Subsequently, more detailed analysis used
PennCNV to collate the copy number variant (CNV) data into Excel tables
and to examine the CNV data to look for unique smaller insertions/deletions.
The genotyping data with AA, AB, and BB were then saved as excel files for
affected and unaffected individuals so that shared regions could be easily
analyzed.
Whole-Exome Sequencing and Bioinformatic Analyses
Whole-exome sequencing was performed within the UK10K project. DNA
(1–3 mg) was sheared to 100–400 bp using a Covaris E210 or LE220 (Covaris).
Sheared DNA was subjected to Illumina paired-end DNA library preparation
and enriched for target sequences (Agilent Technologies; Human All Exon
50 Mb - ELID S02972011) according to manufacturer’s recommendations
(Agilent; SureSelectXT Automated Target Enrichment for Illumina Paired-End
Multiplexed Sequencing). Enriched libraries were sequenced using the HiSeq
platform (Illumina) as paired-end 75 base reads according to manufacturer’s
protocol. The mean coverage of the exomes was 74 times. The Burrows-
Wheeler Aligner (Li and Durbin, 2009) was used for alignment to the humanell Reports 3, 1795–1805, June 27, 2013 ª2013 The Authors 1799
Figure 2. Activated Cryptic Splice Site Downstream to the c.42+1G/ C Mutation Causes a Frameshift and Introduces a Premature Stop
Codon in mRNA
(A) Schematic demonstrating location of c.42+1G/Cmutation withinNDUFA4 intron 1, and homozygousmutation in forward genomic DNA (gDNA) sequencing
of an affected subject. Position of cryptic splice site activated adjacent to the next GT dinucleotide 4 bp downstream of c.42+1G / C is marked with an
asterisk (*).
(B) Silver-stained polyacrylamide gel of amplified complementary DNA (cDNA) extracted from blood and cultured skin fibroblasts alongside a 249 bp molecular
weight marker (M). In blood, III-3 and III-4 (affected siblings) have a strongly stained (mutant) band at 245 bp and a faintly stained (wild-type) band at 241 bp,
(legend continued on next page)
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Figure 3. Steady-State NDUFA4 Protein
Levels Are Undetectable in Muscle Tissue
and Cultured Skin Fibroblasts of Patients
Harboring Homozygous c.42+1G / C Mu-
tations
(A) Western blot analysis of an SDS poly-
acrylamide gel loaded with 10 mg of mitochondrial
protein pellets extracted from muscle tissue and
cultured skin fibroblasts of the affected subjects
(III-4, III-6, III-13 muscle tissue, III-4 cultured skin
fibroblasts) and controls (C1–8). Blots were
developed with antibodies directed against SDHA,
MTCO2, and NDUFA4. The antibody to complex II
subunit SDHA was used to confirm equal protein
loading.
(B) Micrographs of control and affected subject
(III-4) fibroblasts immunocytochemically stained
for NDUFA4 (red fluorescence) andMTCO1 (green
fluorescence) and counterstained with the DNA
fluorochrome 4’,6-diamidino-2-phenylindole (blue
fluorescence). Note that NDUFA4 is absent from
patient cells, whereas MTCO1 levels are compa-
rable to the control cells.reference genome build UCSC hg19 (Grch37). To improve raw alignment
BAMs for SNP calling, we realigned around known (1000Genomes pilot) indels
and recalibrated base quality scores using GATK (DePristo et al., 2011). Base
alignment quality tags were added using SAMtools calmd. BAMs for each
sample were merged and duplicates marked using Picard. Variants (SNPs
and indels) were called on each sample individually with both SAMtools
mpileup (0.1.17) (Li et al., 2009) andGATKUnifedGenotyper (1.3.21) (McKenna
et al., 2010), restricted to exon bait regions plus or minus a 100 bp window.
Various quality filters were applied to each of the callsets separately. Calls
were then merged, giving preference to GATK information when possible.
Calls were annotated with 1000 Genomes allele frequencies, dbSNP132
rsids, and earliest appearance in dbSNP. Functional annotation was added
using Ensembl Variant Effect Predictor v2.2 against Ensembl 64 and in-
cluded coding consequence predictions, SIFT, PolyPhen and Condel
annotations, and GERP and Grantham Matrix scores. Variant filtering of the
single-nucleotide variants and indels was done as previously described on
the basis of autosomal recessive inheritance. The filtering of the variants
was done very stringently, excluding variants in dbSNP132, 1000 Genomes,
synonymous, and other noncoding variants apart from essential splice site
changes. Variants were also excluded if present in either the remainingwhereas II-2 (unaffected father) has a strongly stained band at 241 bp and a faintly stained band at 245 bp.
245 bp. The control blood (C1) and cultured skin fibroblasts (C2) only have a band at 241 bp.
(C) Schematic depicting the mutant NDUFA4 transcript retaining 4 bp of intron 1, with sequencing electrophe
inspection of the mixed electropherogram 50 of exon 2 in III-4 confirmed that wild-type sequence was prese
Mutant sequence can also be seen in II-2. Abbreviations: 1F and 4R, exonic primer binding sites; TAA, prem
See also Table S4.
Cell Reports 3, 1795–180UK10K rare disease cohort (823 exomes at
the time of the analysis) or the NHLBI ESP
database.
Sanger Sequencing
Confirmation and segregation of the c.42+1G/C
mutation and screening of 20 additional COX-
deficient probands for mutations in NDUFA4 was
assessed using standard PCR-based sequencing.
Amplitaq Gold 360 Mastermix (Applied Bio-
systems) was used for all PCRs. Oligonucleotides
for NDUFA4 PCR amplification and sequence
analysis in gDNA are listed in Table S4. M13 se-
quences to prime sequencing reactions wereadded to the 50 end of the primers. Amplification of NDUFA4 fragments for
sequencing of cDNA was performed using a forward primer annealing in
exon 1 (50-GTCAGGCCAAGAAGCATCC-30) and a reverse primer annealing
in exon 4 (30-TTCAGCTTGCTGTAATCCACA-50). Primers were designed using
Primer3 (http://frodo.wi.mit.edu/primer3/), and Sanger sequencing was
performed using M13 primers and BigDye Terminator v.1.1 cycle sequenc-
ing kit (Applied Biosystems). The samples were run on a 3730xl DNA Analyzer,
assembled, and analyzed using Seqscape v2.5 software (Applied
Biosystems).
Transcriptional Analysis
RNA was extracted from whole blood using the QIAGEN/PreAnalytix
blood RNA system and from cultured cells using the QIAGEN/RNeasy
Mini Kit following the manufacturer’s instructions. cDNA was synthesized
from 1 mg RNA in a 20 ml reaction using the Applied Biosystems high-
capacity cDNA reverse transcription kit, following the manufacturer’s
instructions.
Polyacrylamide Gel Electrophoresis of cDNA
Amplified cDNA fragments were resolved on a denaturing 7% polyacrylamide
gel and stained with silver as previously described (Sambrook and Russell,
2001).In cultured skin fibroblasts, III-4 only has a band at
rograms below (reverse sequencing shown). Close
nt at low levels (also seen in III-3, data not shown).
ature stop codon.
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anti-NDUFA4
anti-NDUFA9
anti-UQCRC2
anti-MTCO1
anti-MTCO2
III-4ControlC
Native
Denaturing
100 kDa
50 kDa
37 kDa
25 kDa
20 kDa
15 kDa
10 kDa
aa
bb
c
dd d de
e
55 kDa 125 kDa 400 kDa 600 kDa 55 kDa 125 kDa 400 kDa 600 kDa
CI CIII2+?CIII2CIV CI CIII2+?CIII2CIV
B anti-MTCO1 (Control)anti-NDUFA4 (Control)
0.01 0.02 0.04 0.08 0.16 0.32 % DDM0.01 0.02 0.04 0.08 0.16 0.32 % DDM
CIV
NDUFA4
CIV
A
C1 C2 C3 III-4 III-6 C1 C2 C3 III-4 III-6
Complex IVComplex I
1149 1243 1075 927 1014 1737 1102 906 386 322
(legend on next page)
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Table 2. Clinical Characteristics of Subjects III-3, III-4, III-6, and III-13 with Homozygous c.42+1G/ C Splice Donor Site Mutations in
NDUFA4
Clinical Manifestations
Subject Age (years) Clinical Phenotype DD FTT LD Dystonia Myoclonus Ataxia UMN Signs Seizures
III-3 32 CLA, LS L + + +    
III-4 34 CLA, LS L, M  + + + + + +
III-6 Died 26 CLA, LS L  +     
III-13 Died 8 CLA, LS L, M + + +  + + 
CLA, congenital lactic acidosis; DD, developmental delay; FTT, failure to thrive; L, language; LD, learning difficulties; LS, Leigh syndrome; M, motor;
UMN, upper motor neuron. +, present; , absent.Protein Analysis
Immunocytochemistry
Immunocytochemistry of the NDUFA4/MTCO1 and NDUFA4/MitoTracker Red
CM-H2XRos- (Life Technologies) stained cells was carried out as described
(Taanman et al., 1997b), except that anti-MTCO1 (clone 1D6E11A8, Abcam)
was detected with goat anti-mouse IgG Alexa Fluor 488 (Life Technologies),
anti-NDUFA4 (Stratech Scientific Ltd, AssaybioTech cat. no. C16821) with
goat anti rabbit-IgG Alexa Fluor 594 or 488 (Life Technologies), and nuclei
were counterstained with 1 mg of 40,6-diamidino-2-phenylindole (Sigma) per
ml of Citifluor-glycerol-PBS solution (Agar Scientific).
Western Blot Analysis of Denaturing and Blue-Native
Polyacrylamide Gels
We evaluated protein steady-state levels using western blot analysis of SDS-
denaturing polyacrylamide gels probed with antibodies directed against
NDUFA4 and MTCO2 (clone 12C4F12, Abcam), performed as previously
described (Williams et al., 2004).
To establish the optimal concentration of DDM required to analyze NDUFA4
as part of COX holoenzyme, we performed western blot analysis of 8%–16%
polyacrylamide gradient blue-native gels loaded with 10 mg of mitochondrial
protein extracted from control muscle tissue using serial dilutions of DDM
(0.01%, 0.02%, 0.04%, 0.08%, 0.16%, and 0.32%) for mitochondrial mem-
brane protein extraction (Scha¨gger, 1995; Williams et al., 2004). Blots were
developed with antibodies directed against NDUFA4 and MTCO1. Mitochon-
drial membrane proteins (10 mg), extracted using 0.08%DDM in order to verify
colocalization of the NDUFA4 protein with complex IV, were subsequently
applied and run on 3%–12% polyacrylamide gradient blue-native gels. For
two-dimensional analysis, a single lane was excised from the gel, denatured
with 1% SDS and 2% b-mecaptoethanol, and resolved by denaturing electro-
phoresis in the second dimension on an SDS polyacrylamide gel, prior to
immunoblotting. Blots were probed with specific antibodies against complex
I (anti-NDUFA9; clone 20C11B11B11, Abcam), complex III (anti-UQCRC2;
clone 13G12AF12BB11, Abcam), complex IV (anti-MTCO1, anti-MTCO2),Figure 4. NDUFA4 Subunit andCOXEnzymeComplex Interact in Contro
Detectable with No Abnormal Subassemblies in Patient Muscle
(A) In-gel activity of complex I and IV in 3%–12% polyacrylamide blue-native ge
control (C1–3) and patient (III-4 and III-6) muscle tissue. Complex I activity is comp
in complex IV activity is demonstrated in patient muscle tissue. Smearing of com
measured staining intensity is indicated below each lane.
(B)Western blot analysis of blue-native polyacrylamide gels loaded with 10 mg of m
concentrations of n-dodecyl b-D-maltoside (DDM) were used to extract mitoc
Proteins were run on 8%–16%polyacrylamide gradient blue-native gels to visualiz
to examine the complex IV associations (right panel).
(C) Mitochondrial membrane proteins (10 mg), extracted using 0.08% DDM in o
Figure 4B), were applied and run on 3%–12% polyacrylamide gradient blue-na
analysis, a single lane was excised from the gel, denatured, and resolved by dena
prior to immunoblotting. One-dimensional native blots are shown above two-dime
with specific antibodies against complex I (anti-NDUFA9), complex III (anti-UQCRC
obtained by reprobing one-dimensional blots for SDHA to detect complex II (
of complex V (400 kDa), and the free subunit (55 kDa). CI, complex I; CIII2, compl
NDUFA9.
Cand NDUFA4. Native markers were obtained by reprobing one-dimensional
blots for SDHA (anti-SDHA clone 2E3GC1FB2AE2, Abcam) to detect complex
II (125 kDa) and ATP5A1 (anti-ATP5A1 clone 7H10BD4F9, Abcam) to detect
holocomplex V (600 kDa), the F1 portion of complex V (400 kDa) and the
free subunit (55 kDa).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four tables and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2013.05.005.
LICENSING INFORMATION
This is an open-access article distributed under the terms of the Creative Com-
mons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are
credited.
ACKNOWLEDGMENTS
We are extremely grateful to the family for their participation in this study and
the UK10K consortium for making the research possible. We would like to
dedicate this discovery to the memory of John Alun Morgan-Hughes (June
16, 1932 to August 2, 2012). Funding for UK10Kwas provided by theWellcome
Trust under award WT091310. R.D.S.P. is funded by Medical Research Coun-
cil (MRC) grant (G0800674), and Y.W. was funded by a Wellcome Research
Training Fellowship. S.R., F.M., and J.-W.T. are supported by Great Ormond
Street Hospital Children’s Charity. M.G.H. is supported by an MRC Centre
grant (G0601943) and the Myositis Support Group. A.R.F. is a Muscular Dys-
trophy Campaign Fellow, and S.C. is supported by the EU FP7 Bio-NMD grant
to F.M. This study was supported by the UK NHS Specialised Service for Rarel Muscle, whereas COXEnzymeComplexwithout NDUFA4Subunit Is
ls loaded with 70 mg of mitochondrial enriched protein pellets extracted from
arable among the control and affected subjects. However, significant reduction
plex I can be seen in C3 and III-4 due to high amount of protein loaded. The
itochondrial protein pellets extracted from control muscle tissue. The following
hondrial membrane proteins: 0.01%; 0.02%; 0.04%; 0.08%; 0.16%; 0.32%.
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Table 3. Laboratory, Neurophysiological, Imaging, Histopathological, and Biochemical Characteristics of Subjects III-3, III-4, III-6, and
III-13 with Homozygous c.42+1G/ C Splice Donor Site Mutations in NDUFA4
COX/CS COX (k/min/mg)
Subject
Plasma
Lactate
CSF
Lactate NCS Brain MRI Brain MRS
Muscle
Pathology Muscle
Fibroblasts
(glucose)
Fibroblasts
(galactose)
III-3 3.5–6.6 — sensory
axonal
neuropathy
aged 32: [T2 signal
deep WM, thalami,
brainstem, cerebellum
— — — — —
III-4 1.6–2.4 3.2 sensory
axonal
neuropathy
aged 17: normal
Aged 25: [T2 signal
deep WM
— [lipid 0.008 2.2 1.07
III-6 2.5–4.7 — — aged 25: [T2 signal
parietal WM, BG,
thalami, brainstem
— [lipid 0.004 — —
III-13 2.1–8.5 6.4 — aged 2: [T2 signal
parietal WM
[lactate peak
in BG
global YCOX,
[lipid
— 1.7 —
BG, basal ganglia; COX, cytochrome c oxidase; CS, citrate synthase; CSF, cerebrospinal fluid; NCS, nerve conduction studies; MRS, magnetic reso-
nance spectroscopy; WM, white matter. Reference ranges: plasma lactate 0.7–2.1 mmol/l; CSF lactate <2 mmol/l; COX/CS in muscle 0.014–0.034;
COX/CS in glucose-grown fibroblasts >1; COX/protein in galactose-grown fibroblasts 3.35–3.88 k/min/mg. —, test not performed.Mitochondrial Diseases of Adults and Children and the NIHR UCLH/UCL
Biomedical Research Centre and was undertaken at University College Lon-
don Hospitals/University College London, which received a proportion of fund-
ing from the Department of Health’s National Institute for Health Research
Biomedical Research Centres funding scheme.
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